LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

PXS sp performing to form! .... what a load of rubbish they are - and for my sins i hold some too

Patience cynic.....the sp is quite low considering the potential...if you want some : buy now...before it goes to 10p plus as I expect them to win big contracts and there should be big percentage royalties rolling in soon....I mean ; an aspirin replacement ?...sounds fabulous with the sp being knocked down....at 8p plus I'd be grumbling about getting in but not at this price.

i wonder if i shall live long enough to see 10p

Only 36 days to Xmas cynic. Forget the oranges and apples or whatever healthy stuff goes in your Xmas stocking. Stick Sirco in it instead! ;o)

give your mrs one tooo.....................sirco that is.,.

Or, to put it another way.....Sirco is good for your Elf!

An RNS at last:

Provexis PLC



Development Agreement with DSM Nutritional Products



Provexis plc ("Provexis" or the "Company"), the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, announces that it has entered into a development agreement (the "Agreement") with DSM Nutritional Products ("DSM" and together with Provexis, the "Partners") to commercialise DSM owned intellectual property through the development of a product for the promotion of healthy blood glucose levels.



Under the Agreement, it is the intention that Provexis will develop a cost effective product, carry out clinical trials and gain the necessary regulatory clearances. DSM will contribute intellectual property and know-how to the development programme and will assist in areas such as obtaining regulatory clearances. The Partners will together identify the most appropriate commercialisation arrangements before the product is launched.



Maintaining healthy blood glucose levels, both before and after meals, is of increasing importance as it is believed that high blood glucose levels contribute to obesity and diabetes. The benefits of maintaining healthy blood glucose levels are considered to be increasingly relevant not only in diabetics and pre-diabetics but also in the wider population as a whole. It was estimated in 2010[1] that 25.8 million US residents (8.3% of the population) suffer from diabetes, with an estimated 79 million Americans over the age of 20 having pre-diabetes. It is believed that people with diabetes have a higher than average risk of developing cardiovascular disease[2]. Sales of foods and drinks specifically marketed to address heart health conditions are growing strongly and were forecast to reach $7.7 billion in the US and Europe in 2010[3].



Stephen Moon, CEO of Provexis commented:



"We are delighted to announce this development agreement which further extends our strategic relationship with DSM Nutritional Products. In recent months we have assessed the technology and we believe that it will strengthen further our pipeline of cardiovascular-related technologies. The collaborative approach facilitated by the agreement will allow for the most effective commercialisation of the technology. In addition to this important new pipeline technology, the management team continues to assess further potential acquisitions."

this (and ANR) has been one of my prize stinkers which i try to sweep and keep under the carpet

I was once very enthusiastic about this one but am so glad I sold a long time ago, though by no means at its peak because as that time I was 'sure' it would go further... Greed, as always

"The collaborative approach facilitated by the agreement will allow for the most effective commercialisation of the technology."

Just as it has with Sirco! :o(

Hey Toya...you've come out of the closit......

Mistress T! .... what a pleasure, as one might say!!

Hi cynic and bb - glad you two are still keeping your eyes on all this. I'm not spending much time trading these days - just having the odd 'punt' but mainly holding longer term. Good job I didn't cling onto these too long - though they may turn around eventually I guess.

a rare positive day here with heavy volume too, but as in the past, don't be surprised to see it all disappear back down the plughole

strange things look to be happening here ...... rise is FA in monetary terms but it has been in/out of auction 2/3/4 times already ..... no news that i have seen

Probally another occassion where the PI is not privy to info til tommorow. in this case monday!!

Sold out the other week at a loss......just waited for me to do so (:(((

www.relaxzenshots.com/products/day-flight

just for info - avr volume is 4m pd and already 7.5m

From Stockopedia today:

This week at Stockopedia Central we spoke to Stephen Moon, the chief executive of functional and medical food group Provexis plc a company whose share capital is 70 per cent held by private investors. Like many science-based small-caps, Provexis and its shareholders have had to wait several years for product development to reach the all-important licensing stage. Some nifty footwork around tough new EU regulations and a novel profit-sharing alliance with a major distributor look to have sealed a bright future for the company. That just leaves the companys CEO to begin developing a pipeline of new product candidates to capitalise on that success.
Edit plus: all eyes will be on Provexis in June when it reports in financial